Biocon Limited has announced its participation in JP Morgan's annual flagship India Credit Investor Trip, scheduled for March 11, 2026. The biotechnology company informed both BSE and NSE about this upcoming investor engagement through a regulatory filing dated March 05, 2026.

Event Details

The investor conference will be conducted in a virtual format, allowing for group interactions with analysts and institutional investors. The following table outlines the key details of the scheduled event:

Regulatory Compliance

Biocon has filed this intimation pursuant to Regulation 30(6) of the SEBI Listing Regulations, which requires companies to inform stock exchanges about scheduled meetings with analysts and institutional investors. The company has emphasized that no Unpublished Price Sensitive Information (UPSI) will be disclosed during the analyst and investor meeting.

Important Considerations

The company has noted that the mentioned schedule is subject to change due to exigencies on the part of investors or the company. This flexibility clause is standard practice for such investor interactions, allowing for adjustments based on unforeseen circumstances.

Information Accessibility

Biocon has confirmed that details about this investor conference will be made available on the company's official website at www.biocon.com . This ensures transparency and provides stakeholders with easy access to relevant information about the company's investor engagement activities.

The regulatory filing was signed by Rajesh U. Shanoy, Company Secretary and Compliance Officer, with membership number ACS 16328, and was digitally signed on March 05, 2026.

Biocon Limited has completed a strategic investment of ₹315 crore in two of its wholly owned subsidiaries through Optionally Convertible Redeemable Non-Cumulative Preference Shares (OCRPS). The pharmaceutical major disclosed this transaction under Regulation 30 of the SEBI Listing Regulations to support the ongoing business and working capital requirements of its subsidiaries.

Investment Overview

The company invested in preference shares across two subsidiaries to strengthen their operational capabilities:

Subsidiary Operations and Performance

Biocon Biosphere Limited (BBSL) was incorporated on December 24, 2019, and operates in pharmaceutical manufacturing of API and generic formulations through greenfield facilities in Vizag and Bengaluru. The company has demonstrated strong growth momentum:

Biocon Pharma Limited (BPL) was incorporated on October 31, 2014, and focuses on development and manufacture of generic formulations for global markets, particularly the United States, Europe, and Rest of the World markets. BPL operates a formulations manufacturing facility for oral solid dosages at Bengaluru:

Strategic Purpose and Compliance

The OCRPS investment is specifically designed to support:

• Ongoing business requirements
• Working capital needs
• Capital expenditure requirements
• General corporate purposes

Both transactions fall within the ambit of related party transactions but are exempt from related party transaction provisions under Regulation 23(5) of SEBI Listing Regulations as they involve transactions between a holding company and wholly owned subsidiaries. The transactions were conducted on an arm's length basis, and no governmental or regulatory approvals were required for completion.

Following these investments, Biocon maintains 100% shareholding in both subsidiaries across equity shares and preference shares. The company has confirmed that promoters, promoter groups, or group companies have no additional interest in either subsidiary beyond the holding company relationship.